Unibest

Pharmaceutical intermediates

Dacomitinib Intermediates

1 pharmaceutical intermediate for Dacomitinib. Indication: Carcinoma, Non-Small-Cell Lung.

提交项目All intermediates

About Dacomitinib

Originator
Pfizer Inc
Indication
Carcinoma, Non-Small-Cell Lung
Approved Date
09/27/2018
DS/DP
05/05/2025

Available intermediates

1 intermediate currently listed for Dacomitinib. Request specifications, documentation or a quotation for any item below.

Dacomitinib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
(2E)-4-(1-Piperidinyl)-2-butenoic acid hydrochloride197892-69-6//

Other programs under D

Dabigatran EtexilateDabigatran etexilate mesylateDabrafenib MesylateDanicopanDapagliflozinDaridorexant HydrochlorideDarolutamideDasatinib Hydrate

Building toward Dacomitinib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →